World
CFM warns doctors about prescribing tirzepatide without Anvisa registration
CFM has issued a warning regarding the prescription of tirzepatide without Anvisa registration, including compounded formulations.
The CFM (Federal Council of Medicine) has alerted doctors about the ethical and legal prohibition of prescribing tirzepatide-based medications that do not have a valid health registration with Anvisa (National Health Surveillance Agency). This warning also applies to compounded formulations of the substance that do not comply with health regulations.
Earlier this month, CFM advised healthcare professionals not to prescribe or facilitate access to the active ingredient tirzepatide, known as Mounjaro, without the appropriate registration from the regulatory agency.
The entity emphasizes the importance of complying with regulations to ensure the safety and efficacy of medical treatments. The statement reinforces the responsibility of doctors in using authorized medications.